Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.27) by 37.8 percent. This is a 1.25 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $29.66 million which beat the analyst consensus estimate of $24.91 million by 19.09 percent. This is a 4.25K percent increase over sales of $682.00 thousand the same period last year.